Tiletamine hydrochloride |
![]() Last updated: 16/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A veterinary anaesthetic which is related chemically to ketamine and commonly used in combination with zolazepam | |
---|---|---|
|
Anxiety management. Also used to control convulsions and to induce sedation for veterinary surgical procedures | |
|
Cats; Dogs; Polar bears |
Approval status |
|
Approved - usually supplied as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
---|---|---|
|
Approved |
Chemical structure |
|
Tiletamine hydrochloride exhibits diastereomerism, due to the presence of a chiral centre at the carbon atom adjacent to the cyclohexanone ring. This chiral centre allows tiletamine to exist as two stereoisomers: (R)- and (S)-enantiomers. In commercial formulations like tiletamine is typically used as a racemic mixture. | |
---|---|---|
|
C₁₂H₁₈ClNOS | |
|
CCNC1(CCCCC1=O)C2=CC=CS2.Cl | |
|
- | |
|
ZUYKJZQOPXDNOK-UHFFFAOYSA-N | |
|
InChI=1S/C12H17NOS.ClH/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14;/h5,7,9,13H,2-4,6,8H2,1H3;1H | |
|
Yes |
General status |
|
Medicinal drug, Anaesthetic, Sedative | |
---|---|---|
|
Unclassified medicinal drug | |
|
- | |
|
- | |
|
Synthetic | |
|
NMDA receptor antagonist. It generates a so-called dissociative anaesthesia because it depresses certain cerebral regions whilst other regions, in particular the limbic system, remain active. | |
|
[NMDA receptor, Antagonist] | |
|
14176-50-2 | |
|
604-248-6 | |
|
- | |
|
- | |
|
26543 | |
|
Nervous system: Other general anaesthetics | |
|
QN02AX99 | |
|
No | |
|
- | |
|
259.8 | |
|
2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride | |
|
2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride | |
|
- | |
|
- | |
|
- | |
|
- | |
|
White crystalline solid | |
|
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
Circa 1965, first synthesised; 1980s, global agricultural use begins; 2015, first approvals China | |||
|
|
|||
|
|
|||
|
Typically formulated as part of a combination injectable anaesthetic, most commonly paired with zolazepam hydrochloride | |||
|
The production of tiletamine hydrochloride involves a multi-step synthetic pathway starting with the formation of cyclopentyl 2-thienyl ketone. This key intermediate is typically synthesized via a Friedel–Crafts acylation of thiophene with cyclopentanecarboxylic acid chloride, often catalysed by aluminium trichloride or graphite for improved yields. The ketone is then halogenated and reacted with an amine to form a substituted amino ketone. Through thermal rearrangement and reductive amination, the structure is refined into the active tiletamine base. Finally, the base is treated with hydrochloric acid to yield the hydrochloride salt. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
20000 | Q3 Q = Miscellaneous data from online sources Ethanol3 = Unverified data of known source |
- | ||||||||
|
186 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
352.6 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
160 | Q3 Q = Miscellaneous data from online sources Mouse3 = Unverified data of known source |
Moderate | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
160 | Q3 Q = Miscellaneous data from online sources Mouse3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Metabolised in the liver, excreted via the kidneys | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May cause drowsiness |
Handling issues |
|
|
|||
---|---|---|---|---|
|
IMDG Transport Hazard Code 6.1 | |||
|
Health: H301, H361, H336 | |||
|
Not listed (Not listed) | |||
|
UN2811 | |||
|
Packaging group III (minor danger) | |||
|
- |
|
![]() |
|
|
||
---|---|---|---|
|
tiletamine hydrochloride | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 16/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |